Key Drivers
- Profitability solid
- Leverage elevated
- Cash flow volatile
AIAI Summary
Teva is no longer a distressed generic turnaround but a leveraged branded-neuroscience transition story where the investment case now hinges on AUSTEDO-led growth translating into consistent free cash flow faster than generic erosion and debt reduction, making it a selective execution bet rather than a cheap value play.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability solid
- •Leverage elevated
- •Cash flow volatile
TEVA is profitable and generates solid margins, but high leverage, heavy intangibles, thin liquidity, and volatile cash flow keep the investment case cautious despite manageable interest coverage.
Price Behavior
Key Price Behavior Insights:
- •Higher-low uptrend
- •Resistance Re-test
- •Overbought Risk
TEVA has rebounded sharply over the last month from the low-$31s to the mid-$34s, turning the short-term trend positive above $34.6 but looking somewhat overextended unless it holds $33.2-$33.3 support.
Sharp rebound from $31.48 to $34.64 over the last month signals a fast move and possible pullback risk
Sentiment & News
Key News Insights:
- •Branded Mix Shift
- •CNS Pipeline Build
- •Guidance Pressure
Teva is accelerating its shift from generics toward higher-margin branded and CNS assets, with strong AUSTEDO/Ajovy/Uzedy momentum, biosimilar pipeline progress, and new ecopipam and Emalex-driven growth initiatives, even as full-year guidance disappointed investors.
The news is constructive for Teva's long-term growth story, but near-term upside may be capped until new launches and pipeline execution offset investor concerns on guidance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings